Search Within

Chrisann Kyi Kyi

  1. "Vicky Makker"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (7)
Groups
  1. Department of Medicine (15)
  2. GDMT, Medicine (15)
  3. Gynecologic Medicine Service (15)
  4. Gynecology Disease Management Team (15)
  5. Solid Tumor Oncology Division (15)
  6. Hematologic Malignancies, Division of (14)

More Groups

People
  1. Vicky Makker (15)
  2. Carol Aghajanian (14)
  3. Claire Friedman (14)
  4. Roisin O'Cearbhaill (14)
  5. Rachel Grisham (13)
  6. Alexia Iasonos (12)

More People

Years
  1. 2025 (2)
  2. 2024 (5)
  3. 2023 (1)
  4. 2022 (3)
  5. 2021 (1)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Gynecologic Oncology (5)
  3. International Journal of Gynecological Cancer (3)
  4. Nature Medicine (1)
Publishers
  1. American Society of Clinical Oncology (6)
  2. Elsevier Inc. (5)
  3. Lippincott Williams & Wilkins (3)
  4. Nature Publishing Group (1)

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate
    Journal Article

    Johannet, P.; Flint, M.; Chui, M. H.; Konner, J.; Friedman, C.; Green, A. K.; Guo, R.; Hensley, M. L.; Kyi, C.; Liu, Y.; more...
    Gynecologic Oncology (2025)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary
    Journal Article

    Finch, L.; Andres, S.; Iasonos, A.; Zhou, Q.; Girshman, J.; Chhetri-Long, R.; Green, H.; Selenica, P.; Jang, D.; O'Cearbhaill, R. E.; more...
    International Journal of Gynecological Cancer (2025)

    Fulltext@MSK | Save
  • Efficacy and safety profile of mirvetuximab in folate receptor alpha-positive ovarian cancer
    Meeting Abstract

    Johannet, P.; Foote, M.; Cohen, S.; Friedman, C.; Green, A.; Guo, R.; Hensley, M.; Konner, J.; Kyi, C.; Liu, Y.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer
    Journal Article

    Andres, S.; Finch, L.; Iasonos, A.; Zhou, Q.; Girshman, J.; Chhetri-Long, R.; Green, H.; Jang, D.; O'Cearbhaill, R.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: A case series
    Journal Article

    Sia, T. Y.; Wan, V.; Finlan, M.; Zhou, Q. C.; Iasonos, A.; Zivanovic, O.; Sonoda, Y.; Chi, D. S.; Long Roche, K.; Jewell, E.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)
    Meeting Abstract

    Grisham, R. N.; Li, K.; Zhou, Q.; Iasonos, A.; Girshman, J.; Shah, P.; Jang, D.; Kyi, C.; Cohen, S. M.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save